Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
Identifieur interne : 000127 ( PubMed/Checkpoint ); précédent : 000126; suivant : 000128Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
Auteurs : Jahan S. Khalili [États-Unis] ; Hai Zhu [États-Unis] ; Nga Sze Amanda Mak [États-Unis] ; Yongqi Yan [États-Unis] ; Yi Zhu [États-Unis]Source :
- Journal of medical virology [ 1096-9071 ] ; 2020.
Abstract
Confronting the challenge of the outbreak of COVID-19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of conducting controlled studies during a state of emergency. The access to direct antiviral drugs, such as ribavirin, that have an existing inventory and reliable supply chain may be a priority consideration for therapies developed for the 2019-nCoV infection outbreaks and any strain variants that may emerge. On the basis of the direct antiviral activity of ribavirin against 2019-nCoV in vitro and evidence for potency enhancement strategies developed during the prior SARS and MERS outbreaks, ribavirin may significantly impact our ability to end the lingering outbreaks in China and slow outbreaks in other countries. The apparent COVID-19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of antiviral therapy.
DOI: 10.1002/jmv.25798
PubMed: 32227493
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32227493Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.</title><author><name sortKey="Khalili, Jahan S" sort="Khalili, Jahan S" uniqKey="Khalili J" first="Jahan S" last="Khalili">Jahan S. Khalili</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Hai" sort="Zhu, Hai" uniqKey="Zhu H" first="Hai" last="Zhu">Hai Zhu</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Mak, Nga Sze Amanda" sort="Mak, Nga Sze Amanda" uniqKey="Mak N" first="Nga Sze Amanda" last="Mak">Nga Sze Amanda Mak</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Yan, Yongqi" sort="Yan, Yongqi" uniqKey="Yan Y" first="Yongqi" last="Yan">Yongqi Yan</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Yi" sort="Zhu, Yi" uniqKey="Zhu Y" first="Yi" last="Zhu">Yi Zhu</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32227493</idno><idno type="pmid">32227493</idno><idno type="doi">10.1002/jmv.25798</idno><idno type="wicri:Area/PubMed/Corpus">000112</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000112</idno><idno type="wicri:Area/PubMed/Curation">000112</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000112</idno><idno type="wicri:Area/PubMed/Checkpoint">000127</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000127</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.</title><author><name sortKey="Khalili, Jahan S" sort="Khalili, Jahan S" uniqKey="Khalili J" first="Jahan S" last="Khalili">Jahan S. Khalili</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Hai" sort="Zhu, Hai" uniqKey="Zhu H" first="Hai" last="Zhu">Hai Zhu</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Mak, Nga Sze Amanda" sort="Mak, Nga Sze Amanda" uniqKey="Mak N" first="Nga Sze Amanda" last="Mak">Nga Sze Amanda Mak</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Yan, Yongqi" sort="Yan, Yongqi" uniqKey="Yan Y" first="Yongqi" last="Yan">Yongqi Yan</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author><author><name sortKey="Zhu, Yi" sort="Zhu, Yi" uniqKey="Zhu Y" first="Yi" last="Zhu">Yi Zhu</name><affiliation wicri:level="2"><nlm:affiliation>SystImmune Inc, Redmond, Washington.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>SystImmune Inc, Redmond</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Confronting the challenge of the outbreak of COVID-19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of conducting controlled studies during a state of emergency. The access to direct antiviral drugs, such as ribavirin, that have an existing inventory and reliable supply chain may be a priority consideration for therapies developed for the 2019-nCoV infection outbreaks and any strain variants that may emerge. On the basis of the direct antiviral activity of ribavirin against 2019-nCoV in vitro and evidence for potency enhancement strategies developed during the prior SARS and MERS outbreaks, ribavirin may significantly impact our ability to end the lingering outbreaks in China and slow outbreaks in other countries. The apparent COVID-19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of antiviral therapy.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32227493</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25798</ELocationID><Abstract><AbstractText>Confronting the challenge of the outbreak of COVID-19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of conducting controlled studies during a state of emergency. The access to direct antiviral drugs, such as ribavirin, that have an existing inventory and reliable supply chain may be a priority consideration for therapies developed for the 2019-nCoV infection outbreaks and any strain variants that may emerge. On the basis of the direct antiviral activity of ribavirin against 2019-nCoV in vitro and evidence for potency enhancement strategies developed during the prior SARS and MERS outbreaks, ribavirin may significantly impact our ability to end the lingering outbreaks in China and slow outbreaks in other countries. The apparent COVID-19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of antiviral therapy.</AbstractText><CopyrightInformation>© 2020 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalili</LastName><ForeName>Jahan S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6870-5937</Identifier><AffiliationInfo><Affiliation>SystImmune Inc, Redmond, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>SystImmune Inc, Redmond, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>Nga Sze Amanda</ForeName><Initials>NSA</Initials><AffiliationInfo><Affiliation>SystImmune Inc, Redmond, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yongqi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>SystImmune Inc, Redmond, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>SystImmune Inc, Redmond, Washington.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">novel coronavirus</Keyword><Keyword MajorTopicYN="N">ribavirin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32227493</ArticleId><ArticleId IdType="doi">10.1002/jmv.25798</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Zhang H. Early lessons from the frontline of the 2019-nCoV outbreak. Lancet. 2020;395:687.</Citation></Reference><Reference><Citation>Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020;92:491-494.</Citation></Reference><Reference><Citation>Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.</Citation></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.</Citation></Reference><Reference><Citation>Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-271.</Citation></Reference><Reference><Citation>Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72-73.</Citation></Reference><Reference><Citation>Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):e79.</Citation></Reference><Reference><Citation>Lopinavir/ritonavir, ribavirin and IFN-beta combination for nCoV treatment. 2020. https://clinicaltrials.gov/ct2/show/NCT04276688. Accessed March 3, 2020.</Citation></Reference><Reference><Citation>ChiCTR2000029387. Comparison of efficacy and safety of three antiviral regimens in patients with mild to moderate 2019-nCoV pneumonia: a randomized controlled trial.</Citation></Reference><Reference><Citation>Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID-19. (CTOROTSADTOC). 2020. https://clinicaltrials.gov/ct2/show/NCT04306497. Accessed March 13, 2020.</Citation></Reference><Reference><Citation>Treatment Plan Edition 5 revision edition. 2020. http://www.gov.cn/zhengce/zhengceku/2020-02/09/5476407/files/765d1e65b7d1443081053c29ad37fb07.pdf. Accessed February 10, 2020.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.</Citation></Reference><Reference><Citation>Treatment Plan Edition 5. 2020. www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832ad4be1929091dcbcfca891.pdf. Accessed February 5, 2020.</Citation></Reference><Reference><Citation>World Health Organization. 2019-nCoV situation dashboard. http://who.maps.arcgis.com/apps/opsdashboard/index.html#/c88e37cfc43b4ed3baf977d77e4a0667. Accessed February 21, 2020.</Citation></Reference><Reference><Citation>Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.</Citation></Reference><Reference><Citation>Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090-1095.</Citation></Reference><Reference><Citation>Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol. 2006;16(1):37-48.</Citation></Reference><Reference><Citation>Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A. 2001;98(12):6895-6900.</Citation></Reference><Reference><Citation>Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol. 1998;79(Pt 10):2381-2391.</Citation></Reference><Reference><Citation>Kobayashi T, Nakatsuka K, Shimizu M, et al. Ribavirin modulates the conversion of human CD4(+) CD25(−) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Immunology. 2012;137(3):259-270.</Citation></Reference><Reference><Citation>Li Z, Ping Y, Yu Z, et al. Dynamic changes in CD45RA(−)Foxp3(high) regulatory T-cells in chronic hepatitis C patients during antiviral therapy. Int J Infect Dis. 2016;45:5-12.</Citation></Reference><Reference><Citation>Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999;30(3):376-382.</Citation></Reference><Reference><Citation>Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother. 1999;43(10):2451-2456.</Citation></Reference><Reference><Citation>Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965.</Citation></Reference><Reference><Citation>Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.</Citation></Reference><Reference><Citation>Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-355.</Citation></Reference><Reference><Citation>Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: a new trick for an old drug? CMAJ. 2003;168(10):1289-1292.</Citation></Reference><Reference><Citation>Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci Rep. 2013;3:1686.</Citation></Reference><Reference><Citation>Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014;58(7):928-936.</Citation></Reference><Reference><Citation>Habib AMG, Ali MAE, Zouaoui BR, Taha MAH, Mohammed BS, Saquib N. Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. BMC Infect Dis. 2019;19(1):870.</Citation></Reference><Reference><Citation>Peiris J, Chu C, Cheng V, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767-1772.</Citation></Reference><Reference><Citation>Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986-1994.</Citation></Reference><Reference><Citation>Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348(20):1995-2005.</Citation></Reference><Reference><Citation>Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289(21):2801-2809.</Citation></Reference><Reference><Citation>Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis. 2003;37(8):1139-1142.</Citation></Reference><Reference><Citation>Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.</Citation></Reference><Reference><Citation>Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness. Crit Care. 2016;20:75.</Citation></Reference><Reference><Citation>Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.</Citation></Reference><Reference><Citation>Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019;2:CD010406.</Citation></Reference><Reference><Citation>Russell CM, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395:473-475.</Citation></Reference><Reference><Citation>Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256.</Citation></Reference><Reference><Citation>Ferron F, Subissi L, Silveira De Morais AT, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci U S A. 2018;115(2):E162-E171.</Citation></Reference><Reference><Citation>Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303.</Citation></Reference><Reference><Citation>Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221-18.</Citation></Reference><Reference><Citation>Shah NR, Sunderland A, Grdzelishvili VZ. Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One. 2010;5(6):e11265.</Citation></Reference><Reference><Citation>Lee JY, Kim YJ, Chung EH, et al. The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015. BMC Infect Dis. 2017;17(1):498.</Citation></Reference><Reference><Citation>Mo Y, Fisher D. A review of treatment modalities for Middle East Respiratory Syndrome. J Antimicrob Chemother. 2016;71(12):3340-3350.</Citation></Reference><Reference><Citation>Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.</Citation></Reference><Reference><Citation>Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455-459.</Citation></Reference><Reference><Citation>Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929-936.</Citation></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.</Citation></Reference><Reference><Citation>Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14:69-71.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Washington (État)</li></region></list><tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Khalili, Jahan S" sort="Khalili, Jahan S" uniqKey="Khalili J" first="Jahan S" last="Khalili">Jahan S. Khalili</name></region><name sortKey="Mak, Nga Sze Amanda" sort="Mak, Nga Sze Amanda" uniqKey="Mak N" first="Nga Sze Amanda" last="Mak">Nga Sze Amanda Mak</name><name sortKey="Yan, Yongqi" sort="Yan, Yongqi" uniqKey="Yan Y" first="Yongqi" last="Yan">Yongqi Yan</name><name sortKey="Zhu, Hai" sort="Zhu, Hai" uniqKey="Zhu H" first="Hai" last="Zhu">Hai Zhu</name><name sortKey="Zhu, Yi" sort="Zhu, Yi" uniqKey="Zhu Y" first="Yi" last="Zhu">Yi Zhu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000127 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000127 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:32227493
|texte= Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32227493" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |